Fulltext

Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis

Paoletti, Xavier ; Oba, Koji ; Bang, Yung-Jue ; Bleiberg, Harry ; Boku, Narikazu ; Bouché, Olivier ; Catalano, Paul ; Fuse, Nozomu ; Michiels, Stefan ; Moehler, Markus ; Morita, Satoshi ; Ohashi, Yasuo ; Ohtsu, Atsushi ; Roth, Arnaud ; Rougier, Philippe ; Sakamoto, Junichi ; Sargent, Daniel ; Sasako, Mitsuru ; Shitara, Kohei ; Thuss-Patience, Peter ; Van Cutsem, Eric ; Burzykowski, Tomasz ; Buyse, Marc

In: Journal Of The National Cancer Institute, 2013, vol. 105, no. 21, p. 1667-1670

Aggiungi alla tua lista
    Titre
    • Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis
    Auteur
    • Paoletti, Xavier. Biostatistics Department, INSEM U900 Institut Curie, Paris, Hokkaido, Seoul, Jules Bordet Hospital, Brussels, Reims, Boston, MA, Kashiwa, Biostatistics and Epidemiology Department, Villejuif, Mainz, Kanagawa, Tokyo, Geneva, Paris, Sohara, Rochester, MN, Aichi, Department of Haematology, Oncology, and Tumorimmunology, Berlin, Leuven, Diepenbeek, Louvain-la-Neuve, France, Japan, Korea, Belgium, Japan, France, Japan, France, Germany, Japan, Japan, Switzerland, France, Japan, Japan, Japan, Germany, Belgium, Belgium, Belgium
    • Oba, Koji. Biostatistics Department, INSEM U900 Institut Curie, Paris, Hokkaido, Seoul, Jules Bordet Hospital, Brussels, Reims, Boston, MA, Kashiwa, Biostatistics and Epidemiology Department, Villejuif, Mainz, Kanagawa, Tokyo, Geneva, Paris, Sohara, Rochester, MN, Aichi, Department of Haematology, Oncology, and Tumorimmunology, Berlin, Leuven, Diepenbeek, Louvain-la-Neuve, France, Japan, Korea, Belgium, Japan, France, Japan, France, Germany, Japan, Japan, Switzerland, France, Japan, Japan, Japan, Germany, Belgium, Belgium, Belgium
    • Bang, Yung-Jue. Biostatistics Department, INSEM U900 Institut Curie, Paris, Hokkaido, Seoul, Jules Bordet Hospital, Brussels, Reims, Boston, MA, Kashiwa, Biostatistics and Epidemiology Department, Villejuif, Mainz, Kanagawa, Tokyo, Geneva, Paris, Sohara, Rochester, MN, Aichi, Department of Haematology, Oncology, and Tumorimmunology, Berlin, Leuven, Diepenbeek, Louvain-la-Neuve, France, Japan, Korea, Belgium, Japan, France, Japan, France, Germany, Japan, Japan, Switzerland, France, Japan, Japan, Japan, Germany, Belgium, Belgium, Belgium
    • Bleiberg, Harry. Biostatistics Department, INSEM U900 Institut Curie, Paris, Hokkaido, Seoul, Jules Bordet Hospital, Brussels, Reims, Boston, MA, Kashiwa, Biostatistics and Epidemiology Department, Villejuif, Mainz, Kanagawa, Tokyo, Geneva, Paris, Sohara, Rochester, MN, Aichi, Department of Haematology, Oncology, and Tumorimmunology, Berlin, Leuven, Diepenbeek, Louvain-la-Neuve, France, Japan, Korea, Belgium, Japan, France, Japan, France, Germany, Japan, Japan, Switzerland, France, Japan, Japan, Japan, Germany, Belgium, Belgium, Belgium
    • Boku, Narikazu. Biostatistics Department, INSEM U900 Institut Curie, Paris, Hokkaido, Seoul, Jules Bordet Hospital, Brussels, Reims, Boston, MA, Kashiwa, Biostatistics and Epidemiology Department, Villejuif, Mainz, Kanagawa, Tokyo, Geneva, Paris, Sohara, Rochester, MN, Aichi, Department of Haematology, Oncology, and Tumorimmunology, Berlin, Leuven, Diepenbeek, Louvain-la-Neuve, France, Japan, Korea, Belgium, Japan, France, Japan, France, Germany, Japan, Japan, Switzerland, France, Japan, Japan, Japan, Germany, Belgium, Belgium, Belgium
    • Bouché, Olivier. Biostatistics Department, INSEM U900 Institut Curie, Paris, Hokkaido, Seoul, Jules Bordet Hospital, Brussels, Reims, Boston, MA, Kashiwa, Biostatistics and Epidemiology Department, Villejuif, Mainz, Kanagawa, Tokyo, Geneva, Paris, Sohara, Rochester, MN, Aichi, Department of Haematology, Oncology, and Tumorimmunology, Berlin, Leuven, Diepenbeek, Louvain-la-Neuve, France, Japan, Korea, Belgium, Japan, France, Japan, France, Germany, Japan, Japan, Switzerland, France, Japan, Japan, Japan, Germany, Belgium, Belgium, Belgium
    • Catalano, Paul. Biostatistics Department, INSEM U900 Institut Curie, Paris, Hokkaido, Seoul, Jules Bordet Hospital, Brussels, Reims, Boston, MA, Kashiwa, Biostatistics and Epidemiology Department, Villejuif, Mainz, Kanagawa, Tokyo, Geneva, Paris, Sohara, Rochester, MN, Aichi, Department of Haematology, Oncology, and Tumorimmunology, Berlin, Leuven, Diepenbeek, Louvain-la-Neuve, France, Japan, Korea, Belgium, Japan, France, Japan, France, Germany, Japan, Japan, Switzerland, France, Japan, Japan, Japan, Germany, Belgium, Belgium, Belgium
    • Fuse, Nozomu. Biostatistics Department, INSEM U900 Institut Curie, Paris, Hokkaido, Seoul, Jules Bordet Hospital, Brussels, Reims, Boston, MA, Kashiwa, Biostatistics and Epidemiology Department, Villejuif, Mainz, Kanagawa, Tokyo, Geneva, Paris, Sohara, Rochester, MN, Aichi, Department of Haematology, Oncology, and Tumorimmunology, Berlin, Leuven, Diepenbeek, Louvain-la-Neuve, France, Japan, Korea, Belgium, Japan, France, Japan, France, Germany, Japan, Japan, Switzerland, France, Japan, Japan, Japan, Germany, Belgium, Belgium, Belgium
    • Michiels, Stefan. Biostatistics Department, INSEM U900 Institut Curie, Paris, Hokkaido, Seoul, Jules Bordet Hospital, Brussels, Reims, Boston, MA, Kashiwa, Biostatistics and Epidemiology Department, Villejuif, Mainz, Kanagawa, Tokyo, Geneva, Paris, Sohara, Rochester, MN, Aichi, Department of Haematology, Oncology, and Tumorimmunology, Berlin, Leuven, Diepenbeek, Louvain-la-Neuve, France, Japan, Korea, Belgium, Japan, France, Japan, France, Germany, Japan, Japan, Switzerland, France, Japan, Japan, Japan, Germany, Belgium, Belgium, Belgium
    • Moehler, Markus. Biostatistics Department, INSEM U900 Institut Curie, Paris, Hokkaido, Seoul, Jules Bordet Hospital, Brussels, Reims, Boston, MA, Kashiwa, Biostatistics and Epidemiology Department, Villejuif, Mainz, Kanagawa, Tokyo, Geneva, Paris, Sohara, Rochester, MN, Aichi, Department of Haematology, Oncology, and Tumorimmunology, Berlin, Leuven, Diepenbeek, Louvain-la-Neuve, France, Japan, Korea, Belgium, Japan, France, Japan, France, Germany, Japan, Japan, Switzerland, France, Japan, Japan, Japan, Germany, Belgium, Belgium, Belgium
    • Morita, Satoshi. Biostatistics Department, INSEM U900 Institut Curie, Paris, Hokkaido, Seoul, Jules Bordet Hospital, Brussels, Reims, Boston, MA, Kashiwa, Biostatistics and Epidemiology Department, Villejuif, Mainz, Kanagawa, Tokyo, Geneva, Paris, Sohara, Rochester, MN, Aichi, Department of Haematology, Oncology, and Tumorimmunology, Berlin, Leuven, Diepenbeek, Louvain-la-Neuve, France, Japan, Korea, Belgium, Japan, France, Japan, France, Germany, Japan, Japan, Switzerland, France, Japan, Japan, Japan, Germany, Belgium, Belgium, Belgium
    • Ohashi, Yasuo. Biostatistics Department, INSEM U900 Institut Curie, Paris, Hokkaido, Seoul, Jules Bordet Hospital, Brussels, Reims, Boston, MA, Kashiwa, Biostatistics and Epidemiology Department, Villejuif, Mainz, Kanagawa, Tokyo, Geneva, Paris, Sohara, Rochester, MN, Aichi, Department of Haematology, Oncology, and Tumorimmunology, Berlin, Leuven, Diepenbeek, Louvain-la-Neuve, France, Japan, Korea, Belgium, Japan, France, Japan, France, Germany, Japan, Japan, Switzerland, France, Japan, Japan, Japan, Germany, Belgium, Belgium, Belgium
    • Ohtsu, Atsushi. Biostatistics Department, INSEM U900 Institut Curie, Paris, Hokkaido, Seoul, Jules Bordet Hospital, Brussels, Reims, Boston, MA, Kashiwa, Biostatistics and Epidemiology Department, Villejuif, Mainz, Kanagawa, Tokyo, Geneva, Paris, Sohara, Rochester, MN, Aichi, Department of Haematology, Oncology, and Tumorimmunology, Berlin, Leuven, Diepenbeek, Louvain-la-Neuve, France, Japan, Korea, Belgium, Japan, France, Japan, France, Germany, Japan, Japan, Switzerland, France, Japan, Japan, Japan, Germany, Belgium, Belgium, Belgium
    • Roth, Arnaud. Biostatistics Department, INSEM U900 Institut Curie, Paris, Hokkaido, Seoul, Jules Bordet Hospital, Brussels, Reims, Boston, MA, Kashiwa, Biostatistics and Epidemiology Department, Villejuif, Mainz, Kanagawa, Tokyo, Geneva, Paris, Sohara, Rochester, MN, Aichi, Department of Haematology, Oncology, and Tumorimmunology, Berlin, Leuven, Diepenbeek, Louvain-la-Neuve, France, Japan, Korea, Belgium, Japan, France, Japan, France, Germany, Japan, Japan, Switzerland, France, Japan, Japan, Japan, Germany, Belgium, Belgium, Belgium
    • Rougier, Philippe. Biostatistics Department, INSEM U900 Institut Curie, Paris, Hokkaido, Seoul, Jules Bordet Hospital, Brussels, Reims, Boston, MA, Kashiwa, Biostatistics and Epidemiology Department, Villejuif, Mainz, Kanagawa, Tokyo, Geneva, Paris, Sohara, Rochester, MN, Aichi, Department of Haematology, Oncology, and Tumorimmunology, Berlin, Leuven, Diepenbeek, Louvain-la-Neuve, France, Japan, Korea, Belgium, Japan, France, Japan, France, Germany, Japan, Japan, Switzerland, France, Japan, Japan, Japan, Germany, Belgium, Belgium, Belgium
    • Sakamoto, Junichi. Biostatistics Department, INSEM U900 Institut Curie, Paris, Hokkaido, Seoul, Jules Bordet Hospital, Brussels, Reims, Boston, MA, Kashiwa, Biostatistics and Epidemiology Department, Villejuif, Mainz, Kanagawa, Tokyo, Geneva, Paris, Sohara, Rochester, MN, Aichi, Department of Haematology, Oncology, and Tumorimmunology, Berlin, Leuven, Diepenbeek, Louvain-la-Neuve, France, Japan, Korea, Belgium, Japan, France, Japan, France, Germany, Japan, Japan, Switzerland, France, Japan, Japan, Japan, Germany, Belgium, Belgium, Belgium
    • Sargent, Daniel. Biostatistics Department, INSEM U900 Institut Curie, Paris, Hokkaido, Seoul, Jules Bordet Hospital, Brussels, Reims, Boston, MA, Kashiwa, Biostatistics and Epidemiology Department, Villejuif, Mainz, Kanagawa, Tokyo, Geneva, Paris, Sohara, Rochester, MN, Aichi, Department of Haematology, Oncology, and Tumorimmunology, Berlin, Leuven, Diepenbeek, Louvain-la-Neuve, France, Japan, Korea, Belgium, Japan, France, Japan, France, Germany, Japan, Japan, Switzerland, France, Japan, Japan, Japan, Germany, Belgium, Belgium, Belgium
    • Sasako, Mitsuru. Biostatistics Department, INSEM U900 Institut Curie, Paris, Hokkaido, Seoul, Jules Bordet Hospital, Brussels, Reims, Boston, MA, Kashiwa, Biostatistics and Epidemiology Department, Villejuif, Mainz, Kanagawa, Tokyo, Geneva, Paris, Sohara, Rochester, MN, Aichi, Department of Haematology, Oncology, and Tumorimmunology, Berlin, Leuven, Diepenbeek, Louvain-la-Neuve, France, Japan, Korea, Belgium, Japan, France, Japan, France, Germany, Japan, Japan, Switzerland, France, Japan, Japan, Japan, Germany, Belgium, Belgium, Belgium
    • Shitara, Kohei. Biostatistics Department, INSEM U900 Institut Curie, Paris, Hokkaido, Seoul, Jules Bordet Hospital, Brussels, Reims, Boston, MA, Kashiwa, Biostatistics and Epidemiology Department, Villejuif, Mainz, Kanagawa, Tokyo, Geneva, Paris, Sohara, Rochester, MN, Aichi, Department of Haematology, Oncology, and Tumorimmunology, Berlin, Leuven, Diepenbeek, Louvain-la-Neuve, France, Japan, Korea, Belgium, Japan, France, Japan, France, Germany, Japan, Japan, Switzerland, France, Japan, Japan, Japan, Germany, Belgium, Belgium, Belgium
    • Thuss-Patience, Peter. Biostatistics Department, INSEM U900 Institut Curie, Paris, Hokkaido, Seoul, Jules Bordet Hospital, Brussels, Reims, Boston, MA, Kashiwa, Biostatistics and Epidemiology Department, Villejuif, Mainz, Kanagawa, Tokyo, Geneva, Paris, Sohara, Rochester, MN, Aichi, Department of Haematology, Oncology, and Tumorimmunology, Berlin, Leuven, Diepenbeek, Louvain-la-Neuve, France, Japan, Korea, Belgium, Japan, France, Japan, France, Germany, Japan, Japan, Switzerland, France, Japan, Japan, Japan, Germany, Belgium, Belgium, Belgium
    • Van Cutsem, Eric. Biostatistics Department, INSEM U900 Institut Curie, Paris, Hokkaido, Seoul, Jules Bordet Hospital, Brussels, Reims, Boston, MA, Kashiwa, Biostatistics and Epidemiology Department, Villejuif, Mainz, Kanagawa, Tokyo, Geneva, Paris, Sohara, Rochester, MN, Aichi, Department of Haematology, Oncology, and Tumorimmunology, Berlin, Leuven, Diepenbeek, Louvain-la-Neuve, France, Japan, Korea, Belgium, Japan, France, Japan, France, Germany, Japan, Japan, Switzerland, France, Japan, Japan, Japan, Germany, Belgium, Belgium, Belgium
    • Burzykowski, Tomasz. Biostatistics Department, INSEM U900 Institut Curie, Paris, Hokkaido, Seoul, Jules Bordet Hospital, Brussels, Reims, Boston, MA, Kashiwa, Biostatistics and Epidemiology Department, Villejuif, Mainz, Kanagawa, Tokyo, Geneva, Paris, Sohara, Rochester, MN, Aichi, Department of Haematology, Oncology, and Tumorimmunology, Berlin, Leuven, Diepenbeek, Louvain-la-Neuve, France, Japan, Korea, Belgium, Japan, France, Japan, France, Germany, Japan, Japan, Switzerland, France, Japan, Japan, Japan, Germany, Belgium, Belgium, Belgium
    • Buyse, Marc. Biostatistics Department, INSEM U900 Institut Curie, Paris, Hokkaido, Seoul, Jules Bordet Hospital, Brussels, Reims, Boston, MA, Kashiwa, Biostatistics and Epidemiology Department, Villejuif, Mainz, Kanagawa, Tokyo, Geneva, Paris, Sohara, Rochester, MN, Aichi, Department of Haematology, Oncology, and Tumorimmunology, Berlin, Leuven, Diepenbeek, Louvain-la-Neuve, France, Japan, Korea, Belgium, Japan, France, Japan, France, Germany, Japan, Japan, Switzerland, France, Japan, Japan, Japan, Germany, Belgium, Belgium, Belgium
    Type de document
    • Postprint
    Langue
    • Inglese
    Publié dans
    • Journal Of The National Cancer Institute, 2013, vol. 105, no. 21, p. 1667-1670. Oxford University Press
    Autre version électronique
    Classification
    • Santé
    Identifiant OAI-PMH
    • oai:doc.rero.ch:290990
    Summary
    The traditional endpoint for assessing efficacy of chemotherapies for advanced/recurrent gastric cancer is overall survival (OS), but OS requires prolonged follow-up. We investigated whether progression-free survival (PFS) is a valid surrogate for OS. Using individual patient data from the GASTRIC meta-analysis, surrogacy of PFS was assessed through the correlation between the endpoints and through the correlation between the treatment effects on the endpoints. External validation of the prediction based on PFS was also evaluated. Individual data from 4069 patients in 20 randomized trials were analyzed. The rank correlation coefficient between PFS and OS was 0.853 (95% confidence interval [CI] = 0.852 to 0.854). The R 2 between treatment effects on PFS and on OS was 0.61 (95% CI = 0.04 to 1.00). Treatment effects on PFS and on OS were only moderately correlated, and we could not confirm the validity of PFS as a surrogate endpoint for OS in advanced/recurrent gastric cancer